H

Hansoh Pharmaceutical Group Company Ltd
HKEX:3692

Watchlist Manager
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Watchlist
Price: 18.2 HKD 2.13%
Market Cap: 108B HKD
Have any thoughts about
Hansoh Pharmaceutical Group Company Ltd?
Write Note

Hansoh Pharmaceutical Group Company Ltd
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hansoh Pharmaceutical Group Company Ltd
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
PP&E Gross
ÂĄ3.3B
CAGR 3-Years
-2%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
PP&E Gross
ÂĄ854.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
PP&E Gross
ÂĄ7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
PP&E Gross
ÂĄ3.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
PP&E Gross
ÂĄ2.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
PP&E Gross
ÂĄ534.8m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hansoh Pharmaceutical Group Company Ltd
Glance View

Market Cap
108B HKD
Industry
Pharmaceuticals

Nestled in the heart of China's burgeoning pharmaceutical industry, Hansoh Pharmaceutical Group Company Ltd. stands as a beacon of innovation and resilience. Founded in 1995, Hansoh has carved a niche for itself by focusing on the development, manufacturing, and distribution of a diverse portfolio of drugs. The company has garnered attention by zeroing in on therapeutic areas such as oncology, central nervous system disorders, anti-infectives, and diabetes, aiming to address the pressing needs of a growing patient population. This targeted strategy has not only positioned Hansoh as a formidable player in China's pharmaceutical landscape but also allowed it to compete on a global scale through its commitment to high-quality and affordable healthcare solutions. Hansoh's business model revolves around two core components: research and development (R&D) and strategic distribution. The company has invested heavily in R&D, maintaining an extensive pipeline of innovative drugs that promise to bolster its revenue streams. By focusing on a mix of generic and proprietary medications, Hansoh capitalizes on both established market demands and emerging medical needs. Additionally, its robust distribution network ensures that its products reach a broad array of hospitals and pharmacies, both within China and beyond. This dual approach of scientific advancement paired with efficient delivery mechanisms underpins Hansoh's business success, allowing it to generate steady revenues while paving the way for future growth in international markets.

Intrinsic Value
16.29 HKD
Overvaluation 10%
Intrinsic Value
Price
H

See Also

What is Hansoh Pharmaceutical Group Company Ltd's PP&E Gross?
PP&E Gross
3.3B CNY

Based on the financial report for Dec 31, 2023, Hansoh Pharmaceutical Group Company Ltd's PP&E Gross amounts to 3.3B CNY.

What is Hansoh Pharmaceutical Group Company Ltd's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
16%

Over the last year, the PP&E Gross growth was -5%. The average annual PP&E Gross growth rates for Hansoh Pharmaceutical Group Company Ltd have been -2% over the past three years , 16% over the past five years .

Back to Top